Categories
Sport

Golden State Valkyries unveil jerseys for first WNBA season

  • Kendra Andrews, ESPNDecember 5, 2024, 11:06 p.m. ET

SAN FRANCISCO – The Golden State Valkyries released the uniforms for their inaugural season on Thursday morning. They feature symbols that represent the franchise's ties to the Bay Area and “the strength of the Valkyries.”

Editor's Tips

2 relatives

“The Valkyries’ inaugural uniforms are a visual interpretation of who the Valkyries are: fierce, brave and strong,” said Kimberly Veale, senior vice president of marketing and communications for the Valkyries, in a press release. “When our athletes and fans put on a Valkyries jersey during our inaugural season, they will embody this ethos. These uniforms represent another important milestone for the franchise as we prepare to welcome WNBA basketball to the Bay Area in 2025.”

Golden State's logo is featured on the thread's chest. The logo symbolizes the Bay Bridge, represented by the support cables that form the wings – a key symbol of a Valkyrie. In California, the bridge connects Oakland – where the Valkyries are based and will train – and San Francisco, where they play their home games at Chase Center.

The five triangles formed within the wings represent the five players from the opposing teams facing each other on the field. There are 13 lines radiating from the tip of a sword – another symbol of a Valkyrie – that form the bridge tower and also represent the Valkyries as the 13 WNBA franchise.

Golden State will wear two versions of the uniform. The WNBA Nike Heroine Edition – a white uniform that “symbolizes strength, empowerment and courage,” according to the franchise. The other is the WNBA Nike Explorer Edition, a black jersey with purple details.

Golden State's WNBA Nike Heroine Edition uniforms “symbolize strength, empowerment and courage.” Golden State Valkyries

The next step for Golden State, which will open its inaugural season against the Los Angeles Sparks at Chase Center on May 16, is Friday's expansion draft. The Valkyries can select from a set pool of available players from each of the 12 existing WNBA teams.

The Valkyries will then complete their roster through free agency, which begins in February, and the WNBA Draft in April, where they have the No. 5 pick in each of the three rounds.

Golden State Warriors forward Draymond Green wore a custom black Valkyries uniform to the bench on Thursday night, hours after the official unveiling.

Categories
Health

Prescription Fills for Zepbound, Wegovy Weight Loss Medication Double: GoodRx

A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk.

Reuters

According to data released Thursday by drug savings company GoodRx, the number of prescription blockbuster weight loss drugs in the U.S. more than doubled in 2024, despite limited insurance coverage and high out-of-pocket costs for the treatments.

The numbers are further evidence of insatiable demand for a popular class of drugs called GLP-1 and GIP agonists, which mimic gut hormones to suppress appetite and regulate blood sugar. This includes Novo Nordisk's weight loss medication Wegovy and Eli Lilly's obesity treatment Zepbound, which have hefty list prices of around $1,000 per month without insurance or savings cards.

Prescription drug counts for Wegovy and Zepbound have increased by more than 100% and 300%, respectively, since the start of 2024. Zepbound's increase reflects its first year on the market, as it was approved in the US in November 2023. Wegovy received US approval in 2021.

“It's just a pretty astronomical increase in sales, and for that reason a lot of eyes are on its affordability and accessibility,” said Tori Marsh, director of research at GoodRx, in an interview.

The data comes from GoodRx's new Weight Loss Medications Tracker, which examines filling trends and spending patterns in the U.S. for popular weight loss medications.

According to GoodRx, compliance rates are high, with only 9% of commercially insured people having full Zepbound coverage and 14% having full Wegovy coverage. This refers to insurance coverage that does not require patients to overcome additional hurdles, such as prior approval or higher BMI requirements.

Far higher rates of patients — about 60% to 70% — have insurance plans with more restrictive drug coverage. However, Marsh said that even if a patient has insurance coverage for weight loss treatment, out-of-pocket costs can add up.

The average insured taking Zepbound can expect to pay over $2,500 a year in copays for the drug, she said. GoodRx found that people spent an average of $231 out of pocket on a monthly Zepbound prescription from January 2023 to October of this year.

“Insurance is simply no longer the emergency solution it once was,” Marsh said.

Meanwhile, almost one in five commercially insured people does not have insurance coverage for at least one brand-name GLP-1 and GIP agonist prescribed for weight loss.

GoodRx found that Americans overspent at least $200 million by paying full retail prices for weight-loss drugs instead of using savings options like GoodRx coupons or assistance programs from Eli Lilly or Novo Nordisk. GoodRx said it calculated the overpayment figure based on the average price people could have paid for a drug with a GoodRx discount.

GoodRx says its weight-loss drug coupons can save people without insurance an average of $250 per month or $3,000 per year.

GoodRx's data is consistent with other research indicating that insurance coverage for weight-loss medications is patchy in the United States. For example, a survey released in October found that fewer than a fifth of large employers in the country include the cost of these treatments in their health insurance plans.

The federal Medicare plan also does not cover weight loss treatments unless they are approved and prescribed for another health condition. Research has shown that covering the drugs could significantly increase costs for employers and state and federal governments.

But the Biden administration proposed a rule in November that would allow Medicare and Medicaid to cover weight-loss medications for patients with obesity. If given the green light by the new Trump administration, the rule would significantly expand access to the treatments.

Categories
Technology

The Aachen spin-out FibreCoat secures 20 million euros to carry superfibers into spacecraft

German startup FibreCoat has raised €20 million in Series B funding to bring its super-durable materials to the emerging space industry.

FibreCoat was founded in 2020 by RWTH Aachen. The startup has developed a patented process for coating fibers with metals and plastics during the spinning phase. This creates fibers that are light and conductive, yet strong and durable – at a fraction of the traditional cost. These can then be spun together to form reinforced composite materials.

To date, FibreCoat has focused on winning customers in the automotive, construction and defense industries, where the materials are particularly useful Radiation protection and weight reduction applications. Now things are looking up for the company.

Spacecraft require materials that can withstand extreme temperatures, radiation and electromagnetic interference (EMI) without adding unnecessary weight. “Space is a rapidly growing sector, and launch vehicles and satellites increasingly require coated fibers to withstand harsh conditions,” said Dr. Robert Brull, CEO of FibreCoat.

What day is today? It's CYBER MONDAY!

TNW Conference is offering an exclusive 30% discount on their startup and scaleup programs this week only. This is the best deal you'll get before prices change in January.

Luxembourg-based NewSpace Capital co-led the funding round, bringing key expertise as the startup looks to capitalize on the expanding space ecosystem. projected reach $1.8 trillion by 2035.

“Space and terrestrial supply chains are converging,” said Bogdan Gogulan, managing partner at NewSpace Capital, adding that FibreCoat has the potential to address critical challenges across a variety of industries.

FibreCoat will use the fresh funding to advance research and development and scale production to commercialize its fiber coating technology.

The startup is by no means the only spinout access story to emerge from RWTH Aachen in recent years.

One of the fastest growing is Cylib. The startup is currently building the largest project in Europe Electric vehicle battery recycling plant.

The founders of Cylib – Dr. Lilian Schwich, Paul Sabarny and Dr. Gideon Schwich – founded the company after a decade of research into battery recycling at RWTH Aachen University. The partners say their method uses 30% less energy than the competition.

Another big player is Black Semiconductor, which made gains €254.4 million in June. That's a huge raise for any startup, let alone a European one. What's even more impressive is that the company is only four years old.

The brothers Daniel and Sebastian Schall founded Black Semiconductor in 2020. The startup is developing a novel chip connection technology using the “miracle material” graphene.

Categories
Entertainment

Timothy Hyder charged with allegedly murdering his fiancée

A Florida man, Timothy Hyder, allegedly opened fire on his ex-fiancée after she ended their engagement. According to PEOPLE, after the incident, Hyder reportedly told the victim's daughter, who was reportedly present at the scene, to contact 911.

RELATED: Prayers up! Florida grandfather dies after heated argument about music with neighbors on Thanksgiving

Details surrounding a Florida man's arrest in the fatal murder of his ex-fiancée

The Miami Herald reports that Timothy Hyder and his ex-fiancée Natalie “Dawn” Du'Mee had been together for about three years before the tragic event occurred. According to the outlet, the couple attended a party where Natalie told Timothy that she no longer planned to marry him. After they returned home, she reportedly returned the engagement ring and reiterated her stance.

Police said Du'Mee's daughter, who was upstairs watching a movie, allegedly saw Hyder enter the room and go to a closet shortly after midnight. Moments later, he got a gun, went downstairs to confront Natalie and asked her if she was serious about not getting married before allegedly shooting her in the head.

According to PEOPLE, Natalie Du'Mee's daughter heard the shots and later found her mother with serious injuries to her head and mouth. She claimed that Timothy Hyder confessed to killing her mother after the incident.

“It’s over, I shot her brains out,” Hyder reportedly said. He then told her to call 911.

When officers arrived at the scene on December 1, they found Natalie sitting on the back porch with a gunshot wound to the right side of her head. Police also discovered a handgun lying open on the kitchen counter.

According to police, Hyder immediately admitted he felt remorse for his actions. “He wished he could undo what happened and that he freaked out.” officials explained.

More on Timothy Hyder's charges and what's next for him?

PEOPLE reveals that Timothy Hyder is charged with first-degree murder in the death of 58-year-old Natalie Du'Mee. He was taken into custody and taken to prison on Sunday, December 1st. It is currently unknown if he has legal representation or has filed a lawsuit.

Following the tragedy, St. Cloud Police Chief Douglas Goerke expressed his condolences in a statement.

“During this unimaginably difficult time, our thoughts are with the victim and his relatives,” said Police Chief Goerke in the press release.

RELATED: Say WHAT?! Florida mother arrested and charged after allegedly shooting her 15-year-old daughter at McDonald's

What do you think, roommates?

Categories
Science

MAUVE: A mission idea for an ultraviolet astrophysics probe

Over the past thirty years, NASA's Great Observatories—the Hubble, Spitzer, Compton, and Chandra space telescopes—have revealed some amazing things about the universe. In addition to providing some of the deepest glimpses of the universe enabled by the Hubble Deep Fields campaign, these telescopes have provided glimpses into the invisible parts of the cosmos – that is, the infrared, gamma-ray and ultraviolet spectra. Because of the success of these observatories and the James Webb Space Telescope (JWST), NASA is considering future missions that would reveal even more of the “invisible universe.”

This includes the UltraViolet Explorer (UVEX), a space telescope that NASA plans to launch in 2030 as the next Astrophysics Medium-Class Explorer mission. In a recent study, a team led by researchers at the University of Michigan proposed another concept, known as the Mission to Analyze the UltraViolet universE (MAUVE). This telescope and its sophisticated instruments were designed during the first NASA Astrophysics Mission Design School. According to the team's paper, this mission would hypothetically be ready to launch by 2031.

The study was led by Mayura Balakrishnan, a graduate student in the Department of Astronomy at the University of Michigan. She was joined by researchers from the Laboratory for Atmospheric and Space Physics (LASP), the Institute for Gravitation and the Cosmos (IGC), the Center for Cosmology and AstroParticle Physics (CCAPP), the Kavli Institute for Astrophysics and Space Research and European Space Agency (ESA), the Space Telescope Science Institute (STScI), NASA's Goddard Space Flight Center, NASA's Jet Propulsion Laboratory and several universities. The paper detailing their findings appeared in the Astronomical Society of the Pacific.

NASA's Solar Dynamics Observatory captured these images of solar flares in the extreme ultraviolet wavelengths. Photo credit: NASA/SDO

Over the past fifty years, ultraviolet observatories have revolutionized our understanding of the universe. However, observations of astrophysical phenomena in the ultraviolet (UV) wavelength range are only possible at high altitudes or in space due to interference from the Earth's atmosphere, which absorbs UV radiation very efficiently. The co-author of the study, Dr. Emily Rickman, ESA astronomer and science operations scientist at STScI, told Universe Today via email:

“UV astronomy offers us insights into high-energy events that cannot be detected at other longer wavelengths, such as the visible or infrared wavelengths, and for which a much larger pool of facilities is available. Observation in the ultraviolet region has made significant advances in our understanding of the universe by studying star formation, galaxy formation, and high-energy events on planets in both our solar system and exoplanetary star systems.

“Some of the most notable areas of this understanding have been the detection of ultraviolet radiation from stellar winds emitted by young massive stars. This helps us figure out how such massive stars formed in the early universe.” On the planetary side, UV astronomy has allowed us to observe active aurorae at the poles of Jupiter and how these are influenced by solar storms on the Sun. These active auroras on Jupiter were unexpected and opened up a whole new understanding of the planets, their atmospheres and how they interact with their surroundings.”

The first UV satellite, the Orbiting Astronomical Observatory 2 (OAO 2), was launched in 1968, shortly before the highly anticipated launch of Apollo 8 (the first manned mission to the Moon). Among its many achievements, OAO 2 enabled the early characterization of the absorption of electromagnetic radiation by interstellar gas and dust (also known as interstellar extinction). This was followed by the Extreme Ultraviolet Explorer (EUVE), which launched in 1992 and conducted the first full-sky survey of far-UV sources.

Artist's impression of the Neil Gehrels Swift Observatory. Photo credit: NASA

Then came the Far Ultraviolet Spectroscopic Explorer (FUSE) in 1999, which conducted the first systemic studies of the intergalactic medium (IGM). Then there was the Galaxy Evolution Explorer (GALEX), which operated from 2003 to 2013 and conducted the deepest UV survey of the entire sky to date. There are also the ultraviolet and optical telescopes at the Neil Gehrels Swift Observatory and the three UV instruments at the Hubble Space Telescope – the Space Telescope Imaging Spectrograph (STIS), the Wide Field Camera 3 (WFC3) and the Cosmic Origins Spectrograph.

Unfortunately, none of these detectors can probe the cosmos in the far and extreme ultraviolet wavelengths with the level of detail of a PI-guided mission. As Rickman noted, this and other factors have limited UV astronomy to date:

“One of the biggest limitations actually comes from the lack of facilities capable of observing in the UV wavelength range. Because UV observatories must be located in space because Earth's atmosphere blocks most UV radiation, these space-based UV observatories are significantly more expensive to build and operate than ground-based observatories.

“Due to the limited number of UV observatories, currently active observatories such as the Hubble Space Telescope are overcrowded by astronomers around the world, indicating the need and importance of the existence of such observatories. In addition, the extreme UV wavelength is not currently detected by existing instruments, which represents a blind spot for some astronomical phenomena to be studied.”

While the planned Habitable World Observatory (HWO) is expected to have advanced UV capabilities, this mission is still in the early planning stages and is not expected to launch until the 2040s. To this end, the team proposed a UV space telescope concept called “Mission to Analyze the UltraViolet.”
universE (MAUVE), a wide-field spectrometer and imager designed during the inaugural NASA Astrophysics Mission Design School (AMDS) hosted by JPL in response to the announcement of the opportunity in 2023. As Rickman explained:

“The MAUVE mission concept focuses on three main themes in the context of the Astronomy and Astrophysics 2020 Decadal Survey. These topics are “Are we alone?/Worlds and suns in context,” “How does the universe work?/New messengers and new physics,” and “How did we get here?/Cosmic ecosystem.” To answer the question “Are we alone?”, MAUVE aims to investigate sub-Neptune atmospheric escape, which is thought to be due to either photoevaporation or nuclear-driven mass loss. This will help us understand the habitability of the environment of extrasolar systems as well as the formation and evolution of exoplanets and their atmospheres.”

“In addition, MAUVE would study the atmospheric composition of hot gas on giant exoplanets and whether they are affected by equilibrium or nonequilibrium condensation, which is critical to understanding exoplanetary atmospheres and providing clues to where life might exist on them. “ Universe. To understand: “How does the universe work?”

“MAUVE would investigate whether blue kilonovae are driven by radioactive cooling or rapid shock cooling, which is fundamental to understanding explosive phenomena in the Universe, and would also investigate whether Type 1A supernovae arise from a white dwarf containing material from a companion star accumulates, or from …” merger of white dwarfs. And to investigate “How did we get here?” MAUVE would investigate whether diffuse extragalactic emissions come from faint galaxy cluster members and rogue stars or from shocks from cluster mergers.”

Conceptual vision of the Habitable Worlds Observatory. Image credit/©: NASA Goddard Space Flight Center Conceptual Image Lab

These general themes, Rickman said, are important unanswered questions that astronomers are very interested in answering because they underpin our understanding of the universe. By expanding the wavelength range of existing UV observatories, MAUVE would be able to study the types of high-energy cosmological events that could answer some of these questions. Additionally, Rickman said, MAUVE would be allocated a significant portion (70%) of the General Observer's (GO) time:

“[This would allow] to the broader community to propose their observational ideas that could be studied in this largely unexplored parameter space, and answer fundamental questions such as “How do star-forming structures form and interact with the diffuse interstellar medium?”, “What are the most extreme stars and constellations?” “, “How do habitable environments emerge and evolve in the context of their planetary systems?”. The opportunity to explore these questions would provide fundamental insight into some of the building blocks of our understanding of the universe.”

Further reading: arXiv

Like this:

How Load…

Categories
Health

Wall Road mulls knowledge on Amgen weight-loss drug

The Amgen logo is displayed in front of the Amgen headquarters in Thousand Oaks, California on May 17, 2023.

Mario Tama | Getty Images

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health news straight to your inbox. Subscribe here to receive future editions.

Wall Street is mulling over critical data released last week Amgen's experimental weight-loss injection – a potential competitor in the blockbuster obesity drug market.

Some analysts said the early results of the trial's mid-stage appear positive overall. However, they noted that there remain questions about the drug's effectiveness and patient tolerance.

We likely won't get any further answers until the company releases the full data from the study. These include results from a second part of the study, which examines how long MariTide's weight loss lasts.

Investors were initially not happy. Shares of Amgen plunged more than 11% at the market open last Tuesday as results appeared to fall slightly short of Wall Street's high expectations for the drug.

The MariTide injection helped patients with obesity lose up to 20% of their weight on average after one year without plateauing. Ahead of the data release, several analysts said they wanted MariTide to show at least 20% weight loss in the Phase 2 trial, with some hoping for as much as 25%.

Here is the comparison with the existing injections on the market based on recent studies:

  • Novo Nordisk's Wegovy showed that it resulted in 15% weight loss within 68 weeks
  • Eli Lilly's Zepbound helped patients lose more than 22% of their weight within 72 weeks

But in a note last week, Evan Seigerman, an analyst at BMO Capital Markets, said last Tuesday's stock reaction reflected “overly high expectations for percentage weight loss without any emphasis on easier dosing” of the shot.

Specifically, Amgen is testing MariTide as an injection taken once a month or even less often, which would be far more convenient for patients to take long-term than Novo Nordisk and Eli Lilly's weekly injections.

“MariTide data clearly demonstrates that Amgen is a competitor in the obesity and diabetes indications and is today demonstrating compelling weight loss in both indications,” Seigerman said.

In the study, MariTide also helped patients with obesity and type 2 diabetes lose up to 17% of their weight after one year.

The drug's effectiveness could also improve, Jefferies analyst Michael Yee said in a note last week. The 20% weight loss after a year without a plateau could increase to 25% by 18 months, Yee said. He found that, in comparison, Zepbound-induced weight loss largely stagnated for a year.

The most common side effects of MariTide were gastrointestinal in nature, including nausea, vomiting, and constipation. Nausea and vomiting were predominantly mild and occurred in association with the first dose of MariTide.

Amgen said the incidence of nausea and vomiting was also significantly reduced by increasing the dose. This involves starting patients on a lower dose of MariTide and gradually increasing it over a period of time until they reach a higher target dose.

Approximately 11% of patients in the dose escalation groups discontinued treatment due to adverse side effects, while less than 8% discontinued treatment specifically due to gastrointestinal side effects such as nausea and vomiting.

Amgen reported that 70% of patients in dose escalation groups experienced nausea and 40% experienced vomiting.

However, Amgen said it conducted another early-stage study that found that when patients start MariTide, the starting dose was lower, these rates were significantly reduced, resulting in about 50% of patients over Nausea and 20% reported vomiting.

This appears to be higher than the levels of nausea and vomiting seen with Zepbound and Wegovy. Still, Seigerman said the low severity of these side effects and “the discrete events early in treatment make us confident that they are manageable.”

He added that he was “encouraged by the reductions observed with dose increases.”

In a research note last week, JPMorgan analyst Chris Schott said Amgen would examine lower starting doses in its Phase 3 trial of MariTide. The company believes that “further improvement in tolerability in the Ph3 trial will be key to potential acceptance of the compound,” he noted.

David Risinger, an analyst at Leerink Partners, outlined in a note last week key questions that will need to be addressed when the study's full results are released. He said this includes detailed data on how well patients tolerated the drug when no dose escalation was used, as well as data on weight loss in non-diabetic patients who received the highest dose of the drug.

Feel free to send tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

The latest in health tech: GE HealthCare acquires Japanese pharmaceutical company

GE Healthcare's booth is seen ahead of the 2022 China International Fair for Trade in Services (CIFTIS) at the China National Convention Center on August 28, 2022 in Beijing, China.

Yi Haifei | China News Service | Getty Images

GE Healthcare announced Monday that it will fully acquire Japanese radiopharmaceutical company Nihon Medi-Physics (NMP). According to a statement, GE HealthCare has held a 50% stake in the company since 2004 and will acquire the remaining half from Sumitomo Chemical.

Tokyo-based NMP was founded in 1973. The company makes radiopharmaceuticals, a special type of radioactive medicine that can be used to treat some types of cancer and perform imaging tests. NMP operates 13 manufacturing facilities and conducts its own research and development, GE HealthCare said.

Radiopharmaceuticals are becoming an increasingly competitive market as companies like it Bristol Myers Squibb, AstraZenecaEli Lilly and Novartis Race to develop them. Two Novartis radiopharmaceuticals, Pluvicto and Lutathera, are already available in the United States

According to the press release, NMP generated sales of approximately $183 million last year. Prior to Monday's announcement, GE HealthCare held three seats on NMP's board.

“This will strengthen our precision care strategy in Asia and our existing presence in Japan, where our contrast agents and medical devices are used daily to enable imaging procedures across the country,” said Kevin O'Neill, president and CEO of GE's Pharmaceutical Diagnostics segment HealthCare, the press release says.

Terms of the deal were not disclosed and closing is expected to close early next year, according to the press release. The takeover is still subject to official approval.

Solomon Partners advised GE HealthCare on the transaction.

GE HealthCare announced the acquisition during the Radiological Society of North America's 2024 Annual Meeting in Chicago, where it shared a number of additional updates. This week, the company unveiled a new 3D MRI research baseline model, a new SPECT/CT solution, and a new submission to the U.S. Food and Drug Administration, among other things.

Read the full press release about GE HealthCare's acquisition of NMP here.

Feel free to send tips, suggestions, story ideas and data to Ashley at ashley.caroot@nbcuni.com.

Categories
Sport

Inside Lonzo Ball’s unprecedented 1,000-day return to the NBA

  • Ramona Shelburne

    Close

    Ramona Shelburne

    ESPN Senior Writer

    • Senior writer for ESPN.com
    • Spent seven years at the Los Angeles Daily News
  • Jamal Collier

Dec 5, 2024, 08:00 AM ET

THE OPERATIONS TEAM at Chicago’s O’Hare International Airport knows how to handle snow. With more than 250 pieces of snow removal equipment, they can clear paths in even the most difficult conditions for the planes to keep flying. Chicago Bulls guard Lonzo Ball headed to the airport in the middle of one of those storms. Light rain earlier in the day had turned to snow. Wind gusts approached 20 mph. It was the afternoon of Feb. 16, 2023.

Over the All-Star break, Ball had decided to fly to Salt Lake City to undergo a nerve-block procedure to cut off the pain signals piercing through his knee. He arrived early to give himself time to walk to his gate. Everything he did took extra time. Stairs, escalators, security checkpoints. Carrying his luggage.

The plane was scheduled to take off for the nearly three-hour flight at 7:35 p.m. Shortly before, Ball boarded with the other passengers, only to deplane when a flight attendant announced the plane had mechanical issues. Ball stayed at the gate, waiting for updates. Hours went by. He laid down on the cold, carpeted O’Hare floor, headphones in. He tried to stay patient. If his long, frustrating rehab journey had taught him anything, it was that getting upset doesn’t get you anywhere faster.

After a few more hours, he reboarded the plane with the hope Chicago’s famed snow removal team would clear a runway. Another hour passed before a flight attendant announced it wasn’t safe to take off. Everyone deplaned — again.

At 9 a.m. the next morning, the flight finally took off. Ball wasn’t on it.

“Looking back at it,” he told ESPN, “it was a blessing I didn’t do it.”

Instead of flying to Utah for the nerve block, Ball rerouted to Los Angeles to come up with a new plan. He wanted to play basketball again. But at this point, he had a simpler goal: He just wanted to be able to walk his dog and play with his daughter.

After more than a year of rehabilitation from what was originally thought to be a minor knee injury, he was further away from the court than ever. His knee still throbbed when he went up or down stairs. Anything resembling running was excruciating. And most troubling of all, his latest MRI looked worse than when he first got hurt.

He was 400 days into a recovery that was supposed to last fewer than 60.

“I had literally had a surgery where they just just cut my leg open to see what was going on. Just a search and rescue,” Ball said of a September 2022 procedure. “Once that happened, I was like, ‘I’m not doing this anymore. I need to set a goal … [get everyone] on the call and come up with a plan.”

He’d already undergone two different surgeries, MRIs, injections and months and months of grueling, painful, unproductive rehab. Pain continued to ping through his knee. He knew he needed a new plan altogether, even if it meant undergoing yet another surgery, one no player in the NBA had ever attempted, let alone come back from.

“We tried so many different things. … Finally we’re like, look this is all you got left,” Dr. Brian J. Cole, Ball’s orthopedic surgeon, told ESPN.

“This is a Hail Mary.”

The knee injuries that kept Lonzo Ball out for over two seasons began with an innocuous jammed knee early in 2022. Kamil Krzaczynski-USA TODAY Sports

THE PLAY THAT set Ball on an unprecedented 1,009-day journey was wholly unremarkable. He was playing defense in the first half of a game against the Golden State Warriors on Jan. 12, 2022, and felt his knee jam as he came off a down screen.

Things like that happen all the time in the NBA. Most of the time the player shakes it off, ices it after the game and suits up again the next night. Ball didn’t even come out of the game. It wasn’t until he jammed the knee again, landing after making a layup with 4 minutes to go in the second quarter, that he began to suspect something might actually be wrong.

Ball’s expression did not change at all after the play. No reporter after the game even bothered to ask if he was hurt. The story of that game was actually Zach LaVine going down with a left knee injury and the Bulls, who were 27-12 and leading the Eastern Conference at the time, being humbled on their home court by the Warriors in an 138-96 defeat.

It was a reality check game for a Bulls team that had been a fun, first-half surprise that season after acquiring Ball, DeMar DeRozan and Alex Caruso in the offseason. The Warriors, of course, went on to win the championship that year.

Editor’s Picks

2 Related

“I don’t think you [had] a full grasp of how smart he was and how much he meant to our team until he went down,” LaVine told ESPN. “He was pretty much the glue. He made everything run offensively. Him and Alex defensively were taking a challenge on guys and making it easy for me and DeMar to go out there and do our jobs. He was getting us six to eight points without even really thinking.”

Ball was ruled out of the game the following day because of left knee soreness, an injury everyone initially believed was minor. But after a week, head coach Billy Donovan announced that Ball wasn’t responding to the team’s treatment plan and would need further testing. The next day, Ball was diagnosed with a bone bruise and small meniscus tear in his left knee that would require arthroscopic surgery. The scheduled recovery time was six to eight weeks, right in time for the playoffs.

Six weeks later, the Bulls released a video, showing Ball lifting weights and running at the team’s practice facility. “Feeling pretty good,” Ball said in the video. “Obviously, it’s a slow process. I definitely want to get back on the court as soon as possible.”

Soon after, pain began to radiate across his knee. He tried sprinting on the court, but his knee hurt. Then the Bulls training staff told him to try running on a track. It still hurt. Scaling back, they tried high marches and skips. The pain remained.

“It would work for a day, a week, but his knee just kept hurting,” Brian Serrano, a Bulls athletic trainer, told ESPN. “And it kept getting worse.”

In the meantime, the Bulls had fallen from surprise leader of the Eastern Conference to clinging to the No. 6 seed. On April 6, they pulled the plug, ruling Ball out for the rest of the 2021-22 season.

“At first, I’m thinking four to six weeks, be back for the playoffs,” Ball said. “We got a good team. I’ll have a couple of weeks to get back, ready, and I’ll be fine.

“When that didn’t happen, we started trying all these shots, stuff like that, trying to kill my nerves. I was like, “This s— just don’t feel right. I’m doing a bunch of stuff and it’s not … translating into any good.”

On April 28, the day after the Bulls were eliminated by the Milwaukee Bucks in the first round of the playoffs and more than three months since his injury, Ball sat for his exit interview. He had no answers.

He said his knee recovery was at a standstill.

Ball’s journey began at UCLA before he was selected by the Los Angeles Lakers in the 2017 NBA draft. Photo by Brian Rothmuller/Icon Sportswire

THE BASKETBALL WORLD was introduced to Lonzo Ball during his freshman year at UCLA in 2016-17. He was a whiz at point guard, organizing the Bruins’ offense like Magic Johnson used to do with the Showtime Era Los Angeles Lakers. And he was a winner, guiding UCLA to an upset of then No. 1 Kentucky, in Lexington, and the team’s best record since 2007-08.

His father, LaVar, was front and center for all of it, making sure the world knew just how good his son was and who had raised him. LaVar and his family became something of a cultural phenomenon. He told anyone who would listen that his two younger sons, LiAngelo and LaMelo, would become NBA players, too.

Their mother, Tina, was spotted at UCLA games early in the season but rarely acknowledged beyond a quick camera shot in the stands.

Then, in February 2017, Tina disappeared from the stands and public life — a fact that went unnoticed for nearly a month as the Bruins were in the heart of Pac-12 play and preparing for the NCAA tournament.

The 2024 Emirates NBA Cup

What to know about the NBA’s in-season tournament, including the Dec. 17 final in Las Vegas.

Updates and FAQ on format, prize money
Quarterfinals: The eight-team bracket
Roundtable: Group-play MVP, surprises, more
• All 30 NBA teams reveal new court designs
Windhorst: How LeBron, Lakers won last year

Outwardly, the 18-year-old Lonzo gave nothing away, but his world had been shattered. His mom had suffered a serious stroke that required life-saving surgery to relieve the pressure on her brain.

“My cousin called me at 3 a.m. and was like, ‘Your mom’s about to die,'” Ball said recently. “I just went right home. I didn’t tell nobody. I talked to my dad, and he was like, ‘She’s going to be OK.’ He’s like, ‘I got her. Just go play.'”

March Madness was days away. The NBA draft was in June. All the fame and fortune LaVar had been preparing Lonzo for had finally arrived. The task was to compartmentalize. It was soul-crushing.

“I didn’t get to see her until I got back home, in the summer,” Ball said. “She was in the hospital the whole time.

“It was really hard. I went home for a day, then got sent right back out.”

Ball talks to his mom every day now. She’s better, though her right side and speech haven’t fully recovered.

She’s the reason, he said, why he has been able to persevere through the injuries and the uncertainty, why he has never given in to self pity, no matter how painful or frustrating it became.

“I see the stuff that she goes through and it’s like that’s 10 times worse than what I have to deal with,” he said. “It just puts things into perspective.”

Ball began his NBA career wearing Big Baller Brand shoes, a company started by his family. Photo by Andrew D. Bernstein/NBAE via Getty Images

TALENT EVALUATORS USED to wonder whether Ball loved the game or was just trained by his father to play a certain way. What some read as calm decision-making, others read as a lack of passion.

It has been eight years since the world first got to know LaVar Ball and his three basketball-playing sons. Since the Big Baller Brand was born, selling $495 shoes — some of which actually got delivered.

It was a sensational story, and LaVar was determined to milk every bit of it. He signed the family up to do a reality show for Facebook called, “Ball in the Family.” He started his own youth basketball league, the Junior Basketball Association, after pulling his youngest son, LaMelo, out of high school. He built out the Big Baller Brand with a clothing line, bottled water and even hot sauce.

It was hard to tell where LaVar ended and Lonzo began. Which parts were LaVar’s dreams, and which were his sons’?

Did they want to be NBA basketball players as much as he wanted them to? Did Lonzo actually want to wear Big Baller Brand shoes?

“I was an Adidas kid since high school, so I was thinking that was going to be the route,” Ball said. “But what was told to me, I guess, wasn’t what really happened. I was told that nobody wanted to partner with me, so my dad was like, ‘Just rock the brand.’ And I was like, ‘All right.'”

The problem, Ball said, was that the first shoes his dad had made for him to wear at NBA summer league in 2017 were unwearable.

“They were like kickball shoes,” Ball said. He wore them just twice that summer. He and his manager, Darren Moore, went out to Foot Locker stores in Las Vegas to buy a different pair of high-end shoes for each game. Ball played one game each in the Air Jordan XXXI, Nike Kobe A.D., Adidas Harden LS and Under Armour Curry 4 en route to winning summer league MVP.

Eventually, Big Baller Brand set up an arrangement with Sketchers to manufacture its shoes, which Ball wore for his entire rookie season. But Ball said he wasn’t happy with those shoes either and believes they could have contributed to the first meniscus injury he suffered as a rookie in January 2018.

“I think it’s a possibility for sure, to be honest with you,” Ball said. “I wasn’t really getting hurt like that until I started wearing them.”

Back in 2018, Ball chose the surgery with the quickest recovery time, hoping to return to help the Lakers make a playoff push in his first season. It seemed like the right choice for a 20-year-old with no history of knee issues. Ball missed 15 games and returned after the All-Star break, but by that point the Lakers were eight games back of eighth place in the West. After they were eliminated from the playoff race in late March, the Lakers shut Ball down for the season.

2025 NBA draft

• New mock draft: All 30 first-round picks
• Flagg: Recent history | Improbable rise
• 10 college teams with most NBA prospects
• From No. 1 to 100: New player rankings
• Predictions: Early chances at No. 1 pick
• NBA teams with most draft picks | More

Looking back on all the problems he has had with that left knee over the past six years, Ball said he wonders if there were already cartilage issues deep within his knee before he even reached the NBA — thanks to years of playing on concrete and running sprints in Chino Hills State Park.

“My uncle used to always tell me, ‘Y’all play too much outside,’ because we were playing super hard in the backyard. That’s on concrete,” Ball said. “That was at least 15 years. So I mean, all that, over time, it can’t be good for your knees.”

He has had years to think about all of this — the outdoor courts, the sprints, the shoes. Years and years to wonder why this all happened to him. To question. To doubt. And yet in all that time, one emotion that hasn’t seeped in is regret.

“I don’t feel like I would be where I’m at, if I didn’t do all that stuff,” Ball said. “All the work that we put in, it could have hurt, but it also made us who we are. “

There’s no doubt in anyone’s mind anymore whether this was his dream or his father’s. Whether he loved the game or had simply been trained to play it.

“I’ve loved it my whole life,” Ball said.

JOHN MEYER GETS desperate calls from athletes all the time. The famed rehabilitation specialist in Los Angeles has made a career out of helping athletes through daunting injuries and complex surgeries.

He first met Lonzo Ball in May 2022 when the Bulls asked him to give a fresh perspective on why this seemingly minor issue wasn’t getting better.

Meyer put Ball through every cutting-edge test in his biomechanics lab in Los Angeles: artificial-intelligence-powered muscle analytics from a rapid MRI machine, three-dimensional cameras and force plates to create a strength profile of his whole body. The data indicated he needed to work on his hip and knee strength, so that’s what they focused on during the offseason.

“As he rehabilitated and continued to push to return, he continued to wear down his knee,” Meyer said. They kept running MRIs but couldn’t find an answer to Ball’s pain.

The Bulls had Serrano fly to Los Angeles throughout the offseason to help with Ball’s recovery. They were banking on his return for the next season, after seeing what their team could be with Ball as their engine.

“[Ball] was willing to try everything, do anything,” Serrano said. “If we told him, we need you here at 8, he was here, 8. …. He was doing some sort of therapy, manual therapy, stretching, strength conditioning every day.

NBA on ESPN+

Get access to exclusive original series, premium articles from our NBA insiders, the full 30 for 30 library and more. Sign up now to unlock everything ESPN+ has to offer.

At the NBA draft in June, Bulls general manager Marc Eversley was asked whether Ball would be ready for training camp. Eversley said he certainly hoped so.

Meanwhile, in Los Angeles, Ball could barely do a one-legged squat. He’d sit on a small stool, bend his left knee while keeping the right leg straight. The pain was excruciating and unrelenting.

It had been eight months since his initial surgery. Dr. Neal ElAttrache, a famed orthopedic surgeon specializing in athletes; Cole, who also serves as the Bulls’ team physician; Meyer; and representatives from Ball’s agency and the Bulls’ front office met to outline a new recovery plan. Cole said Ball saw at least five knee specialists through the rest of 2022.

“There were opinions coming in from all over the country,” Cole said.

With training camp approaching, they decided to perform a second knee surgery. Officially, it’s called an “arthroscopic debridement,” a cleanup of any broken tissue, bone or cartilage from a previous surgery. Unofficially, Ball called this a “search and rescue mission,” the kind of operation the Coast Guard performs when someone is lost at sea.

A day before his second surgery in eight months, Ball spoke to reporters on a Zoom call from Los Angeles. “I still can’t play basketball,” he said. “I can’t run or jump. There’s a range from, like, 30 to 60 degrees when my knee is bent that I have no force. And I can’t catch myself. I did rehab. It was getting better. But it was not to a point where I could get out there and actually go out there and run at full speed or jump. So surgery was the next step.”

With Ball sidelined to start the season, the Bulls fell under .500 by the middle of November. Ball returned to Chicago about once a month for rehab, and his teammates would greet him excitedly.

“I would just text him, like, occasionally check in and see how he was doing,” Bulls guard Coby White told ESPN. “If I saw a Bible verse, I would send it to him as motivation. … Because when you are in that situation, you want to give him his space. Just check in here and there.

“We didn’t want to be overwhelming. He’s already got a lot of pressure on him and things going through his head. So we ain’t going to add to that stress.”

Five months later, in February 2023, Ball began to feel new pain in the inside of the joint, in the weight-bearing portion of his femur. Another MRI showed cartilage in the area beginning to separate from the bone. The Bulls ruled him out for the rest of the season. It was suggested he fly to Salt Lake City for an extensive nerve-blocking procedure to ease the pain.

“He was really struggling,” Meyer said. “Just trying to understand, ‘Why does it still hurt?’

“And at that point, we were kind of talking about [the rest of his] life, not really basketball.”

Moore, who has known Ball since he was 7 years old, wondered more than once whether his friend had had enough. As delicately as he could, Moore would ask Ball what he’d do if he couldn’t play basketball again.

Ball was still just 25. He had his daughter, Zoe, who he wanted to play with, to run with. He had a girlfriend, Ally Rossel. Still, Ball wasn’t ready to entertain the conversation.

“I just hated that no one could tell me,” Ball said. “Like if you’re a professional, I feel like, ‘You don’t have any type of solution for me?’

“It just didn’t feel right to me.”

Getting stuck at the airport in the snowstorm was the final straw.

After several setbacks, Ball and his team of doctors landed on a “Hail Mary” surgery. EPA/KAMIL KRZACZYNSKI SHUTTERSTOCK OUT

MEYER, COLE, ELATTRACHE, Serrano and Chip Shaeffer, then the Bulls’ director of performance health, convened a new series of calls to come up with a new plan.

This wasn’t a pain issue or a meniscus issue anymore. It was also a cartilage deterioration issue, which injections to promote healing hadn’t helped. Trying to fix old cartilage was just wasting more time.

His best shot to have a normal life, they thought, and maybe play basketball again, was to replace Ball’s cartilage with cartilage from a cadaver, preferably someone around his age. There’d be risk of tissue rejection, risk that the graft doesn’t hold, and then the very real question of whether the cartilage graft could withstand the force and impact of an NBA game.

It’d be a procedure Cole had performed successfully a half-dozen times with NFL and NHL players, but no one had ever attempted it on a basketball player.

The recovery time would be an additional 18 months.

If anything went wrong, or even if everything went right but Ball could recapture only 80% of his previous athleticism, his professional basketball career could be over.

The doctors couldn’t guarantee much of anything, except that this was probably the only option he had left.

“Basically doing this in a high-level athlete — you got to manage expectations,” Cole said.

“It wasn’t just, ‘Hey, do the two-hour surgery and you’re done.’ It’s two years of rehabilitation and maintaining or getting his skills back. And torturing someone else’s tissue in there until it became part of him.

And only Ball could make the decision.

Cole talked with Ball. “Tell me you can’t play, and we can talk about this surgery,” he told him. “But if you can play, I’d rather you play in some pain than go through this, which is unpredictable. God forbid it makes you worse. Nobody knows if it’s going to work — or how long it’ll last. Please, play in pain.”

Ball responded. “I can’t do it.”

They had their answer.

BALL WAS RELIEVED to have a plan and a potential resolution.

“I wish I didn’t have to, but it was the only option left,” Ball said. “I think a lot of people wrote me off, because it was an unknown surgery.

“But at the end of the day, I was 25, so I was like, sit out this time, put the work in and hope for the best.”

In March, Ball underwent the untested cartilage replacement surgery. Three months later, the Bulls announced Ball would miss the entire 2023-2024 season.

Rossel and Moore stayed with him and helped him through those first few months. The only activity he was allowed to do was use a continuous passive motion machine, which moved his knee for him. Everything else had to be done on crutches or in bed.

Get your favorite live sports, stories and originals with ESPN+, Disney+ and Hulu. Upgrade to a Disney Bundle plan and start streaming something for everyone today!

“When he had that machine and it was moving his leg,” Moore said. “I could definitely tell his spirit was fighting. Like, ‘I know I’m going to get back.’ But, ‘Man, this sucks.’ But, ‘I’m fighting.’

“And I told him, ‘Look, man, we’ve been down before and we’ve still been able to create and do great things in s—ty moments.'”

Moore brought up the idea of starting a podcast as an outlet. For months they kicked around ideas, who should be on the podcast with him and whether this was the right move when it still wasn’t clear he’d be able to resume his basketball career. But eventually Ball realized he actually had a lot to say.

The irony of launching his podcast talking about everything in his life, just when he finally got rid of all the cameras and attention that used to follow him everywhere, is not lost on Ball. It’s appropriately titled, “What An Experience.”

“This is different, though,” Ball said. “Because I control it. I’m pushing my own narrative as opposed to somebody telling me what to say, or shooting the scene. ‘Put this in play, and do it like that.’ The cameras that we have now, if I don’t want it to go, I just cut them off.”

Zach LaVine and Ball remained close as they rehabbed injuries together. Kamil Krzaczynski-Imagn Images

THE ONLY CAMERAS around those first few months after the cartilage replacement surgery were Moore’s iPhone and the high-tech cameras in Meyer’s biometrics lab.

Every morning, Ball would drive from his house in Sherman Oaks to Meyer’s facility in El Segundo for an 11 a.m. appointment. They’d work for hours — on movement patterns, walking, loading, strengthening. Measuring everything as they went to determine when his body was ready for more.

Little by little, they started to see improvements.

He’d be able to walk without feeling pain the next day. Eventually they tried the one-legged step down from the stool that had given him so many problems in the past. No pain.

“We weren’t even cautiously optimistic at that point,” Serrano said. “We were just happy he was able to do [day-to-day] activities.”

On Aug. 22, ESPN’s Stephen A. Smith mentioned on “First Take” that he’d heard Ball was having trouble getting up from a sitting position and no one was sure he’d ever play again. The statement would’ve been true a few months earlier. But Ball had made progress by then and was irked enough to respond with a video of himself doing the one-legged squat.

“I’ll never forget the Stephen A. moment,” Moore said. “We were actually in the gym when that happened and he was on his way to getting back onto the floor. … It lit a fire underneath us.”

Throughout the fall, small signs of progress begat unbridled optimism. Ball could still walk without pain. He began completing small exercises without pain. Small jumps, on two legs, then one. Sore, but no pain.

Jumping off one leg was a milestone for Ball — and his doctors.

“That was more than we’d ever done through the conservative care, the other operations, the shots, all that,” Serrano said. “This was further than he’d ever been.”

Running was next.

“I actually held him from running for a long time,” Meyer said. “Because running was where he failed every time coming out of the other surgeries. So I felt like he had a lot of demons when it comes to running. I knew mentally if he failed, it was going to be a big disappointment.”

He passed. On Dec. 28, 2023, more than nine months after the cartilage replacement surgery, and nearly two years since the injury, Donovan announced Ball had been cleared to run.

LaVine soon joined Ball in L.A. after undergoing foot surgery in February.

“He was the same guy, very optimistic and happy, but then you also started to see his competitiveness come back,” LaVine said. “He would start asking like, ‘Let’s go out and shoot, you know, let’s do some shooting games.’ I would see him in the gym shooting, he’ll mess around, throw the ball on me and try to guard me and stuff like that. As he started to feel better, you could see his mood just as a basketball player come back and be like, oh, OK. He’s starting to have some of that itch.”

They continued working out together. LaVine has witnessed the entirety of Ball’s journey — the early highs, the long, deep lows. He was there when Ball stepped foot back in Chicago for his first practice in years, too.

“He gets the ball, flies up the floor like he was never hurt, sets a back screen for a guy, gets it back, splits a pick and roll and then does a no-look pass to Jaylen Smith,” he said. “I remember I was just sitting there, I was like, holy s—.”

ON Oct. 11, 2024, the day Ball had been working toward finally arrived: He announced on his podcast he was cleared by the team’s doctors to play. His first game action in 1,009 days would come on Oct. 16, in the Bulls’ fourth preseason game against the Minnesota Timberwolves.

Inside the United Center, Ball warmed up with Serrano at half court. He was on a strict minutes restriction, four four-minute stints, one in each quarter.

Midway through the first quarter, Donovan called Ball’s number from the bench. As Ball walked to the scorer’s table, the home crowd exploded with a standing ovation.

Ball threw his hands to the air and tapped his heart as he inbounded the ball. A few possessions later, Ball rewarded them, knocking down a 3-pointer from the corner. As he ran back up the court and threw three fingers up in the air, Bulls fans, who’d watched their team wallow in mediocrity for much of the past three seasons, shook with glee. LaVine ran up the baseline on the opposite end. He fought back tears.

The team gave Lonzo the game ball 🥹 pic.twitter.com/ejpyeXLiFR

— Chicago Bulls (@chicagobulls) October 17, 2024

“I can only imagine how he felt,” Bulls forward Patrick Williams told ESPN. “My heart was pounding for him.”

Cole, the surgeon who performed the “Hail Mary” on Ball’s knee 19 months earlier, was seated near the Bulls bench. “It was like someone who gets a lung transplant [was] able to go for a run,” he said. “I’ve been doing this for 26 years. Probably one of the most special nights I’ve had.”

Ball finished with 10 points on 4-of-6 shooting in 15 minutes. This season, he’s averaging 4.5 points and 3.5 assists in just over 16 minutes per game. He missed 15 games because of a sprain in his right wrist before returning Nov. 27.

After the preseason game against the Timberwolves ended, LaVine made a beeline to grab the game ball from the officiating crew to bring back to the Bulls locker room. LaVine and Coby White are two of only five players still on the team from the last time Ball was on the court.

“Today was going to be a special day regardless of the outcome,” White said in the locker room. “‘Zo back, man.” He tossed the basketball to Ball, who tapped his heart with his right hand and smiled. “This was a hell of a night for him.”

“One more thing,” LaVine said. Sitting at his locker, he held up a jersey with signatures from all of Ball’s current teammates. “I respect you more than anything because of what you’ve been through. We love you, we care about you. Glad to see you back.”

After LaVine and Ball embraced, Ball was mobbed by his teammates, White slapping his head as Ball led the huddle. “Family,” he said, “on three. 1-2-3. Family.”

Categories
Technology

Hyundai believes CarPlay and Android Auto ought to proceed to be choices

Hyundai must be feeling good about the U.S. market right now: The company just posted “record-breaking” November sales, led by its electric and hybrid vehicles.

It wouldn't be too far-fetched for the South Korean automaker to think that it must be doing something right in answering the market's demands. And at least one recurring trait at Hyundai is a willingness to continue offering drivers a flexible range of options.

The most recent example is Hyundai's commitment to continue offering CarPlay and Android Auto, the in-car phone mirroring apps.

“For now, we're still keeping Android Auto and Carplay,” said Olabisi Boyle, Hyundai's senior vice president of product planning, in a new interview with InsideEVs.

Of course, Hyundai has the advantage of having experienced the negative reactions that followed General Motors' decision in 2023 to stop offering the apps for its vehicles. According to a McKinsey study, the unavailability of these apps is enough of a factor to deter almost half of new car buyers.

But it's also part of Hyundai's market approach to keep all options available.

“It’s a bit like charging electric vehicles,” Boyle says. “Give people every opportunity as we move.”

Hyundai vehicles already provided access to charging stations via traditional CCS (Combined Charging System) connectors. However, the automaker decided to also provide Tesla's NACS charging ports for its new Ioniq 5, giving drivers access to over 28,000 SuperChargers in North America.

Of course, companies like Tesla and Rivian never asked themselves whether they should keep or abandon CarPlay and Android Auto: They didn't offer the apps at all, preferring instead to develop their own cutting-edge software and electrical systems.

Boyle believes Hyundai and the entire auto industry could eventually find better alternatives to CarPlay and Android Auto. “This could be the future,” she says.

But in the meantime, Hyundai remains true to its philosophy of covering all bases.



Categories
Entertainment

Nicole Kidman and Keith City's daughter Religion seems to be like mother

Nicole KidmanThis is baby girl Believe Margaret Kidman Urban is completely grown up.

In fact, the 13-year-old was the Oscar winner's plus one at the Hollywood Reporter's annual Women in Entertainment gala on December 4th.

Dressed in a black and white jacket and matching tweed skirt, Faith happily stood next to her mother – who opted for a black dress with a blue blouse-style collar – and mingled with other guests at the Beverly Hills Hotel.

At one point during the star-studded event, Nicole wrapped her arms around Faith and gave her a big hug. Faith then turned to her mother and smiled sweetly as they posed for photos.

Nicole shares Faith and daughter Sunday Rose Kidman Urban16, with husband Keith Urban. The 57-year-old is also a mother of children Bella Cruise31, and Connor Cruise29, from her previous marriage to ex Tom Cruise.

And now that Nicole's youngest children are teenagers, they've been looking to mom's wardrobe for style inspiration.

“You walk into my closet and it looks like a bomb went off,” Nicole joked to Entertainment Tonight in September. “They’re going crazy in there.”

Categories
Science

US “power dominance”: a key to Trump’s peace efforts – does Watt agree?

By Matthew Roy

The energy policy of the USA and Europe towards Russia is characterized by striking contradictions. On the one hand, the Biden administration, flanked by its NATO counterparts, is sending hundreds of billions of dollars in military aid to Ukraine and loudly proclaiming sanctions aimed at weakening the Russian economy. On the other hand, these same nations continue to procure Russian oil, gas and LNG, replenishing the very coffers they claim to be emptying. This hypocrisy is compounded by President Biden's own domestic energy policies, which are restricting American production at the very moment that Europe is faltering in its attempt to wean itself from dependence on Russian energy.

In this context, the new Trump administration's “energy dominance” agenda represents a necessary and impactful realignment. By expanding oil and gas production in the United States, Trump is proposing a strategy that aligns America's energy policy with its geopolitical needs. Such a framework not only improves transatlantic energy security but also enables Trump to negotiate with strength in his promised pursuit of a peace deal with Russia. As ambitious as it is pragmatic, this plan deserves the utmost attention, both for its immediate benefits and for its potential to restore coherence in an area where it has been sorely lacking.

Watching NATO countries distribute billions to Ukraine while simultaneously supporting the Kremlin's war machine through energy purchases, one is struck by the sheer absurdity of this double game. This is not just a bureaucratic oversight, but rather a lack of a comprehensive strategy. The sanctions, ostensibly designed to slow Russia's economy, will become ineffective if Europe turns around and replenishes Moscow's coffers through both direct and backdoor energy trading.

Ostensibly excluded from European markets, Russian crude finds refuge in third countries – primarily in Central and East Asia – where it is blended, refined and, with a hint of plausible deniability, sold back to Europe at an acceptable markup. Consider India: once a negligible player in Russian oil imports, now suddenly the beneficiary of almost 40% of Moscow's exports. Indian refineries convert this crude oil into diesel and other derivatives to then export it back to Europe. It is essentially a proper money laundering operation – one that ensures a steady flow of revenue to Russia while Europe pays handsomely for its pretense of self-righteous isolation. The irony would be amusing if the stakes weren't so high.

Meanwhile, President Biden's time in office has been marked by an almost doctrinaire aversion to reliable energy development in the United States, a legacy that seems less a matter of policy than a point of pride. His intentions were already clear in 2020, when he campaigned under the slogan “ban fracking,” a slogan that is as reductive as it is revealing. On his first day in office, Biden summarily canceled the final phase of the Keystone XL pipeline project, a key artery for North American energy connectivity. By the end of his first week, he had frozen all public land lease applications for oil and gas and placed additional bureaucratic review on existing leases.

Biden then doubled down on his push, endorsing new climate legislation to regulate methane emissions, a homage to Barack Obama's unvarnished ambition to choke off fossil fuel production through the regulatory apparatus. Perhaps most insulting to European allies seeking alternatives to Russian energy, Biden paused authorization for LNG export activities in January 2024. At a moment when America's energy resources could have provided a bulwark against economic instability and geopolitical vulnerability, Biden instead chose to give in to the ideological imperatives of his political base.

While it is true that U.S. LNG exports to Europe have risen to historic highs since the war began in 2022, it is important to realize that this was a market reaction and occurred despite, not because of, Biden's energy policies . Biden's priority has always been to use the government to hamper natural gas development, even as European allies faced a crisis of supply cuts and uncertainty.

The contrast between Donald Trump and Joe Biden on energy policy is a study in opposites. Trump’s slogan “Drill, Baby, Drill” encapsulates a vision of “energy dominance” that is uncompromisingly ambitious, unashamedly pro-development and unmistakably American. In his first term, Trump expedited approvals for the Keystone XL and Dakota Access pipelines, cut through red tape to expedite oil and gas leases, and delivered a remarkable quadrupling of LNG exports.

Now, with billions of dollars of capital hanging in the balance, the energy sector is eagerly awaiting a return to that ethos of decisive action. The permit backlog, a irritant of the Biden administration, has caused projects to stall for months or even years as Washington dithers. Under Trump, the energy industry thrived not through government's vigilant consideration but through liberation from it. With Chris Wright and Doug Burgum selected as energy and interior secretaries, respectively, it is safe to assume that the new administration will once again unleash the free and creative forces that drive American industry.

There are also some in Europe who are looking forward to Trump taking a new direction in energy and foreign policy. Friend and political ally Viktor Orban has opposed the European status quo and sought a negotiated end to violence in Ukraine. Orban's Hungary imports almost 100% of its natural gas, used for heating homes, generating electricity and industrial production, from Russia. Orban is heavily criticized in the West for this realpolitik approach of maintaining normal relations with the only provider of an indispensable resource to which his landlocked country currently has no alternative. But even European Commission President Ursula Von der Leyen, who has been a vocal critic of both Trump and Orban, has recently changed her mind and expressed enthusiasm for a new Trump-style energy policy.

After Donald Trump's election victory, the dialogue between Trump and von der Leyen quickly turned to issues of strategic importance, including a proposal to expand U.S. LNG exports to Europe. “LNG is one of the topics we have raised,” von der Leyen noted. “We still source a lot of LNG via Russia. And why not replace it with American LNG, which is cheaper and lowers our energy prices?” Politico's analysis concludes that this is simply a poster for upcoming tariff negotiations, a face-saving proposal to import more LNG, over trade deficits that Von der Leyen actually cannot enforce. This is a completely plausible interpretation, but there is another outstanding negotiation that is directly affected by this issue, namely a peace agreement between Russia and Ukraine.

After all, energy is never just a microeconomic issue, limited to the concerns of its own industry; It is the sine qua non of the modern economy. As such, it is an essential factor for state security and social stability. By rebalancing Europe's energy dependence on American LNG, Trump has a tool not only for economic leverage but also for geopolitical realignment that could prove indispensable in shaping the contours of peace. In this context, the LNG discussion is not just transactional but symbolic of a broader, more consistent strategy.

To claim that energy trade alone can bring Russia under control would be tantamount to unwarranted optimism. Nevertheless, it is not without use as a negotiating tool. While Ursula von der Leyen's proposal for increased LNG trade is little more than a rhetorical flourish, it still serves a tactical purpose: It signals the kind of seriousness that attracts attention and tilts the negotiating table in the United States' favor. Negotiations are, after all, a complicated ballet of feints, hints and hidden threats – each one designed to unsettle the opponent and realign the balance of power.

With a million dead or injured, Russia's recent liberalization of nuclear doctrine and the deployment of a new nuclear-capable hypersonic missile to the battlefield, the stakes have never been higher and the case for de-escalation and peace never clearer. In a proxy war against a “gas station masquerading as a country,” as John McCain famously characterized Russia, energy policy really matters. Trump's vision is not just a transactional game, but an affirmation of the principle of strength, both economic and military, that is the linchpin of effective diplomacy.

Matthew Roy is an energy industry expert with over a decade of experience in corporate leadership and strategy. He is currently a Visiting Research Fellow for the Budapest Fellowship Program at the Donau Institute with a focus on energy policy.

This article was originally published by RealClearEnergy and made available via RealClearWire.

Like this:

How Load…